{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:37:53Z","timestamp":1789702673891,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      2-deoxy-2[\n                      <jats:sup>18<\/jats:sup>\n                      F]Fluoro-\n                      <jats:sc>d<\/jats:sc>\n                      -glucose (FDG) PET-CT has an emerging role in assessing response to neoadjuvant therapy in oesophageal cancer. This study evaluated FDG PET-CT in predicting pathological tumour response (pTR), pathological nodal response (pNR) and survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Cohort study of 75 patients with oesophageal or oesophago-gastric junction (GOJ) adenocarcinoma treated with neoadjuvant chemotherapy then surgery at Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London (2017\u20132020). Standardised uptake value (SUV) metrics on pre- and post-treatment FDG PET-CT in the primary tumour (mTR) and loco-regional lymph nodes (mNR) were derived. Optimum SUV\n                      <jats:sub>max<\/jats:sub>\n                      thresholds for predicting pathological response were identified using receiver operating characteristic analysis. Predictive accuracy was compared to PERCIST (30% SUV\n                      <jats:sub>max<\/jats:sub>\n                      reduction) and MUNICON (35%) criteria. Survival was assessed using Cox regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Optimum tumour SUV\n                      <jats:sub>max<\/jats:sub>\n                      decrease for predicting pTR was 51.2%. A 50% cut-off predicted pTR with 73.5% sensitivity, 69.2% specificity and greater accuracy than PERCIST or MUNICON (area under the curve [AUC] 0.714, PERCIST 0.631, MUNICON 0.659). Using a 30% SUV\n                      <jats:sub>max<\/jats:sub>\n                      threshold, mNR predicted pNR with high sensitivity but low specificity (AUC 0.749, sensitivity 92.6%, specificity 57.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009\n                      <jats:italic>0.010<\/jats:italic>\n                      ). pTR, mTR, pNR and mNR were independent predictive factors for survival (pTR hazard ratio [HR] 0.10 95% confidence interval [CI] 0.03\u20130.34; mTR HR 0.17 95% CI 0.06\u20130.48; pNR HR 0.17 95% CI 0.06\u20130.54; mNR HR 0.13 95% CI 0.02\u20130.66).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metabolic tumour and nodal response predicted pTR and pNR, respectively, in patients with oesophageal or GOJ adenocarcinoma. However, currently utilised response criteria may not be optimal. pTR, mTR, pNR and mNR were independent predictors of survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:italic>\u2022 FDG PET-CT has an emerging role in evaluating response to neoadjuvant therapy in patients with oesophageal cancer.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>\u2022 Prospective cohort study demonstrated that metabolic response in the primary tumour and lymph nodes was predictive of pathological response in a cohort of patients with adenocarcinoma of the oesophagus or oesophago-gastric junction treated with neoadjuvant chemotherapy followed by surgical resection.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>\u2022 Patients who demonstrated a response to neoadjuvant chemotherapy in the primary tumour or lymph nodes on FDG PET-CT demonstrated better survival and reduced rates of tumour recurrence.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-023-09482-7","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T05:03:41Z","timestamp":1678856621000},"page":"3647-3659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma"],"prefix":"10.1007","volume":"33","author":[{"given":"Jonathan L.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manil","family":"Subesinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Santaolalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Deere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Van Hemelrijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Lagergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugama","family":"Chicklore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Maisey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Gossage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara R.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Guy\u2019s and St Thomas\u2019 Oesophago-gastric Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ngan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Owczarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sita-Lumsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Mahadeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gill-Barman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cominos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sevitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Zeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"issue":"1","key":"9482_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/BJS.9965","volume":"103","author":"H Miyata","year":"2016","unstructured":"Miyata H, Yamasaki M, Makino T et al (2016) Impact of number of [18F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer. Br J Surg 103(1):97\u2013104. https:\/\/doi.org\/10.1002\/BJS.9965","journal-title":"Br J Surg"},{"issue":"10","key":"9482_CR2","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1007\/S00330-016-4227-4","volume":"26","author":"JM Findlay","year":"2016","unstructured":"Findlay JM, Gillies RS, Franklin JM et al (2016) Restaging oesophageal cancer after neoadjuvant therapy with 18F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery. Eur Radiol 26(10):3519\u20133533. https:\/\/doi.org\/10.1007\/S00330-016-4227-4","journal-title":"Eur Radiol"},{"issue":"4","key":"9482_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/bjs.10611","volume":"104","author":"JM Findlay","year":"2017","unstructured":"Findlay JM, Bradley KM, Wang LM et al (2017) Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. Br J Surg 104(4):408\u2013417. https:\/\/doi.org\/10.1002\/bjs.10611","journal-title":"Br J Surg"},{"key":"9482_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bpg.2018.11.009","volume":"36\u201337","author":"K Foley","year":"2018","unstructured":"Foley K, Findlay J, Goh V (2018) Novel imaging techniques in staging oesophageal cancer. Best Pract Res Clin Gastroenterol 36\u201337:17\u201325. https:\/\/doi.org\/10.1016\/j.bpg.2018.11.009","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"2","key":"9482_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2967\/JNUMED.116.176313","volume":"58","author":"JM Findlay","year":"2017","unstructured":"Findlay JM, Bradley KM et al (2017) Predicting pathologic response of esophageal cancer to neoadjuvant chemotherapy: the implications of metabolic nodal response for personalized therapy. J Nucl Med 58(2):266\u2013275. https:\/\/doi.org\/10.2967\/JNUMED.116.176313","journal-title":"J Nucl Med"},{"issue":"12","key":"9482_CR6","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/bjs.10900","volume":"105","author":"AR Davies","year":"2018","unstructured":"Davies AR, Myoteri D, Zylstra J et al (2018) Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. Br J Surg 105(12):1639\u20131649. https:\/\/doi.org\/10.1002\/bjs.10900","journal-title":"Br J Surg"},{"key":"9482_CR7","doi-asserted-by":"publisher","unstructured":"Evans RP, Kamarajah SK, Kunene V, et al. Impact of neoadjuvant chemotherapy on nodal regression and survival in oesophageal adenocarcinoma. Eur J Surg Oncol. 2022;0(0). https:\/\/doi.org\/10.1016\/J.EJSO.2021.12.021","DOI":"10.1016\/J.EJSO.2021.12.021"},{"issue":"1","key":"9482_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/S41588-019-0551-3","volume":"52","author":"A Noorani","year":"2020","unstructured":"Noorani A, Li X, Goddard M, Crawte J et al (2020) Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. Nat Genet 52(1):74. https:\/\/doi.org\/10.1038\/S41588-019-0551-3","journal-title":"Nat Genet"},{"issue":"9","key":"9482_CR9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1470-2045(07)70244-9","volume":"8","author":"F Lordick","year":"2007","unstructured":"Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8(9):797\u2013805. https:\/\/doi.org\/10.1016\/S1470-2045(07)70244-9","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"9482_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y et al (2009) Response criteria in solid tumors. J Nucl Med 50(Suppl 1):122\u2013150. https:\/\/doi.org\/10.2967\/jnumed.108.057307","journal-title":"J Nucl Med"},{"issue":"12","key":"9482_CR11","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1200\/JCO.2001.19.12.3058","volume":"19","author":"WA Weber","year":"2001","unstructured":"Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19(12):3058\u20133065. https:\/\/doi.org\/10.1200\/JCO.2001.19.12.3058","journal-title":"J Clin Oncol"},{"key":"9482_CR12","unstructured":"Union for International Cancer Control (UICC). TNM classification of malignant tumours - eighth edition. J B, editor. Wiley Blackwell"},{"key":"9482_CR13","unstructured":"Siewert JR, Stein HJ. Carcinoma of the gastroesophageal junction - classification , pathology and extent of resection Tumor Type Adeno Ca of the Distal Esophagus True Ca Cardia Anatomical. 1996;173\u201382"},{"key":"9482_CR14","doi-asserted-by":"crossref","unstructured":"Mandard FJ , Dalibard JC, Mandard J, et al. 1994 Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic Correlations. Cancer.73(11)","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C"},{"key":"9482_CR15","doi-asserted-by":"publisher","unstructured":"Textor J, Van Der Zander B, Gilthorpe MS, et al. Software application profile robust causal inference using directed acyclic graphs: the R package \u201cdagitty\u201d; https:\/\/doi.org\/10.1093\/ije\/dyw341","DOI":"10.1093\/ije\/dyw341"},{"issue":"3","key":"9482_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1200\/JCO.2003.04.013","volume":"21","author":"RJ Downey","year":"2003","unstructured":"Downey RJ, Akhurst T, Ilson D et al (2003) Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21(3):428\u2013432. https:\/\/doi.org\/10.1200\/JCO.2003.04.013","journal-title":"J Clin Oncol"},{"issue":"9","key":"9482_CR17","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/J.EJCA.2007.04.001","volume":"43","author":"MK Kim","year":"2007","unstructured":"Kim MK, Ryu JS, Kim SB et al (2007) Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43(9):1385\u20131391. https:\/\/doi.org\/10.1016\/J.EJCA.2007.04.001","journal-title":"Eur J Cancer"},{"issue":"9","key":"9482_CR18","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/S00330-012-2459-5","volume":"22","author":"RS Gillies","year":"2012","unstructured":"Gillies RS, Middleton MR, Blesing C et al (2012) Metabolic response at repeat PET\/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. Eur Radiol 22(9):2035\u20132043. https:\/\/doi.org\/10.1007\/S00330-012-2459-5","journal-title":"Eur Radiol"},{"issue":"29","key":"9482_CR19","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1200\/JCO.2006.06.7801","volume":"24","author":"K Ott","year":"2006","unstructured":"Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24(29):4692\u20134698. https:\/\/doi.org\/10.1200\/JCO.2006.06.7801","journal-title":"J Clin Oncol"},{"issue":"25","key":"9482_CR20","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.20.03611","volume":"39","author":"KA Goodman","year":"2021","unstructured":"Goodman KA, Ou FS, Hall NC et al (2021) Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) Trial. J Clin Oncol 39(25):2803\u20132815. https:\/\/doi.org\/10.1200\/JCO.20.03611","journal-title":"J Clin Oncol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-09482-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-023-09482-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-09482-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T08:17:00Z","timestamp":1682065020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-023-09482-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["9482"],"URL":"https:\/\/doi.org\/10.1007\/s00330-023-09482-7","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Mr. Andrew Davies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Dr. Aida Santaolalla and Professor Mieke Van Hemelrijck (King\u2019s College London) kindly provided statistical advice for this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 Prospective\u2022 observational\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}